05:08 PM EST, 11/04/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) reported Q3 net income late Tuesday of $0.16 per diluted share, down from $0.41 a year earlier.

Four analysts polled by FactSet expected $0.13.

Revenue in the three months ended Sept. 30 rose to $207.6 million from $182.5 million a year earlier.

Four analysts surveyed by FactSet expected $218.5 million.

The company cut its 2025 revenue guidance to the range of $800 million to $850 million from the prior forecast of $850 million to $900 million.

Four analysts polled by FactSet expect $852.6 million.

Corcept shares fell 3.3% in after-hours trading.